Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety is a research paper published in Cancer Medicine (2021). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Memorial Sloan-Kettering Cancer Center
Grant: P30 CA008748 (to C.A)
US Department of Defense Ovarian Cancer Research Program
Grant: OC120506 (to E.M.S)
Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant
Grant: SU2C-AACR-DT16-15 (to E.M.S)
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
Ann Rife Cox Chair in Gynecology and the Judy Reis/Albert Pisani, MD, Ovarian Cancer Research Fund (to R.L.C)
Clovis Oncology, Inc
NIHR Biomedical Research Centre at UCL (to J.A.L)
FWCI
0.32
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals